<DOC>
	<DOCNO>NCT02294006</DOCNO>
	<brief_summary>Abnormal PI3K-Akt-mTOR ( mammalian target rapamycin ) pathway signal autocrine activation mTOR pathway , mediate insulin-like growth factor 1 ( IGF1 ) , implicate proliferation pNET ( primitive neuroectodermal tumor ) cell . Everolimus , mTOR inhibitor ( central regulator growth/proliferation , cellular metabolism angiogenesis ) show antitumor benefit pNETs alone combination Octreotide LAR RADIANT-1 RADIANT-3 study . Despite EVE-based phase II/III trial improve progression-free survival ( PFS ) pNETs , limit significantly prolong overall survival ( OS ) . Metformin recently show anti-cancer activity , vitro vivo study antisecretory property decrease insulin IGF1 level ; antitumor effect due AMPK ( adenosine monophosphate kinase ) activation consequently inhibition TSC1 ( tuberous sclerosis complex 1 ) -2/mTOR complex , mediate LKB1 oncogene expression . The investigator retrospective experience , despite limited group pWDNET , highlight role MET improve clinical benefit diabetic pt receive EVE-OCT ( octreotide ) combination . This study investigate antiproliferative potential MET combination EVE OCT pWDNETs . MetNET1 prospective trial ( EudraCT 2014-000888-41 ) may helpful either confirm discard preliminary finding . The main objective study evaluate progression free survival rate 12 month treatment . The secondary objective safety , overall survival , response rate evaluation . A sub-study analysis evaluate circulant biomarkers level ( IL 6 , IGF1 ) blood sample .</brief_summary>
	<brief_title>Activity Safety Everolimus+Octreotide LAR+Metformin Advanced Pancreatic Well-differentiated NETs</brief_title>
	<detailed_description />
	<mesh_term>Endocrine Gland Neoplasms</mesh_term>
	<mesh_term>Adenoma , Islet Cell</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>1 . Signature write informed consent ( approved Institutional Ethics Committee Independent ) obtain careful study screen procedure 2 . Age &gt; = 18 year old . 3 . Patients histological evidence pNET welldifferentiated G1 G2 4 . Configurable tumor disease ( accord RECIST ( Response Evaluation Criteria In Solid Tumors ) ) . 5 . Karnofsky Performance Status &gt; = 60 % . 6 . Life expectancy great 6 month . 7 . Is permitted enroll patient receive treatment advanced disease patient pretreated surgery , chemotherapy somatostatin analogue . 8 . Basal blood test : Counts neutrophil absolute value &gt; 1.5 x 109 / L. Platelet count &gt; 100 x 109 / L. Hemoglobin &gt; 9 g / dl . Total Bilirubin &lt; 1.5 time upper limit normal . AST ( aspartate aminotransferase ) , ALT ( alanine aminotransferase ) &lt; 2.5 time upper limit normal patient without evidence liver metastasis . AST , ALT &lt; 2.5 time upper limit normal patient evidence liver metastasis . Alkaline phosphatase &lt; 2.5 time upper limit normal patient evidence hepatic metastasis Values serum creatinine &lt; 1.5 mg / dl . CCr ( Creatinine Clearance rate ) ≥ 60 mL / min 9 . During study male female patient must use adequate contraceptive method . 1 . Patients histological evidence malignant insulinoma ( pNET ) 2 . Surgeries perform within 28 day prior start treatment . 3 . Evidence metastasis level central nervous system spinal cord compression . Patients subject recent study MRI CT scan least 28 day date randomization . 4 . Clinically significant cardiovascular disease , cardiovascular accident occur less 6 month , unstable angina , congestive heart failure grade great equal II accord classification New York Heart Association ( NYHA ) series cardiac arrhythmia require treatment . 5 . Important comorbidities , metabolic disorder , clinical examination laboratory investigation , contraindicate use drug study , patient high risk complication treatment . 6 . Active uncontrolled severe infection . 7 . Cirrhosis , acute hepatitis chronic active hepatitis . 8 . Poor control diabetes HbA1c &gt; = 8.0 % . 9 . Diabetic patient treat metformin eligible enabled treatment metformin le 6 month . Are exclude diabetic patient make use hypoglycemic agent sulfonylurea , insulin , glinides monotherapy combination metformin . 10 . Using anti IL6 ( Interleukin 6 ) IGF1 . 11 . Uncontrolled high blood pressure , atrial fibrillation . 12 . History immunosuppression include positive HIV test . 13 . No previous concomitant oncological pathology , except : basal cell skin cancer , situ , long every cancer patient diseasefree least 5 year . 14 . They exclude patient condition metabolic acidosis , acute chronic , include ketoacidosis . 15 . History alcohol abuse , habitual intake alcohol ( ≥ 3 glass alcoholic drink / day ) sufficient cause hepatotoxicity . 16 . Prolonged fasting . 17 . Severe state dehydration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>pancreatic</keyword>
	<keyword>neuroendocrine</keyword>
	<keyword>everolimus</keyword>
	<keyword>metformin</keyword>
	<keyword>octreotide</keyword>
</DOC>